Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Review Article

In vitro Lipolysis as a Tool for the Establishment of IVIVC for Lipid-Based Drug Delivery Systems

Author(s): Ravinder Verma and Deepak Kaushik*

Volume 16, Issue 8, 2019

Page: [688 - 697] Pages: 10

DOI: 10.2174/1567201816666190620115716

Price: $65

conference banner
Abstract

In vitro lipolysis has emerged as a powerful tool in the development of in vitro in vivo correlation for Lipid-based Drug Delivery System (LbDDS). In vitro lipolysis possesses the ability to mimic the assimilation of LbDDS in the human biological system. The digestion medium for in vitro lipolysis commonly contains an aqueous buffer media, bile salts, phospholipids and sodium chloride. The concentrations of these compounds are defined by the physiological conditions prevailing in the fasted or fed state. The pH of the medium is monitored by a pH-sensitive electrode connected to a computercontrolled pH-stat device capable of maintaining a predefined pH value via titration with sodium hydroxide. Copenhagen, Monash and Jerusalem are used as different models for in vitro lipolysis studies. The most common approach used in evaluating the kinetics of lipolysis of emulsion-based encapsulation systems is the pH-stat titration technique. This is widely used in both the nutritional and the pharmacological research fields as a rapid screening tool. Analytical tools for the assessment of in vitro lipolysis include HPLC, GC, HPTLC, SEM, Cryo TEM, Electron paramagnetic resonance spectroscopy, Raman spectroscopy and Nanoparticle Tracking Analysis (NTA) for the characterization of the lipids and colloidal phases after digestion of lipids. Various researches have been carried out for the establishment of IVIVC by using in vitro lipolysis models. The current publication also presents an updated review of various researches in the field of in vitro lipolysis.

Keywords: In vitro lipolysis, IVIVC, lipase, pH stat, lipid based drug delivery systems, lipid digestion, biorelevant media.

Graphical Abstract
[1]
Kalepu, S.; Manthina, M.; Padavala, V. Oral lipid-based drug delivery systems - an overview. Acta Pharm. Sin. B, 2013, 3(6), 361-372.
[http://dx.doi.org/10.1016/j.apsb.2013.10.001]
[2]
Fotaki, N.; Vertzoni, M. Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral for-mulations. Open Drug Deliv. J., 2010, 4, 2-13.
[http://dx.doi.org/10.2174/1874126601004020002]
[3]
Dahan, A.; Hoffman, A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J. Control. Release, 2008, 129(1), 1-10.
[http://dx.doi.org/10.1016/j.jconrel.2008.03.021] [PMID: 18499294]
[4]
Thomas, N.; Müllertz, A.; Graf, A.; Rades, T. Influence of lipid composition and drug load on the in vitro performance of self-nanoemulsifying drug delivery systems. J. Pharm. Sci., 2012, 101(5), 1721-1731.
[http://dx.doi.org/10.1002/jps.23054] [PMID: 22294458]
[5]
Patton, J.S.; Carey, M.C. Watching fat digestion. Science, 1979, 204(4389), 145-148.
[http://dx.doi.org/10.1126/science.432636] [PMID: 432636]
[6]
Kollipara, S.; Gandhi, R.K. Pharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulations. Acta Pharm. Sin. B, 2014, 4(5), 333-349.
[http://dx.doi.org/10.1016/j.apsb.2014.09.001] [PMID: 26579403]
[7]
Dai, W.; Xu, W. In vitro high through put drug precipitation methods for oral formulations. Am. Pharm. Review, 2012, 243, 1-8.
[8]
Benito-Gallo, P.; Franceschetto, A.; Wong, J.C.; Marlow, M.; Zann, V.; Scholes, P.; Gershkovich, P. Chain length affects pancreatic lipase activity and the extent and pH-time profile of triglyceride lipolysis. Eur. J. Pharm. Biopharm., 2015, 93, 353-362.
[http://dx.doi.org/10.1016/j.ejpb.2015.04.027] [PMID: 25936853]
[9]
Larsen, A.T.; Sassene, P.; Müllertz, A. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. Int. J. Pharm., 2011, 417(1-2), 245-255.
[http://dx.doi.org/10.1016/j.ijpharm.2011.03.002] [PMID: 21392564]
[10]
Mohsin, K.; Long, M.A.; Pouton, C.W. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: Precipitation of drug after dispersion of formulations in aqueous solution. J. Pharm. Sci., 2009, 98(10), 3582-3595.
[http://dx.doi.org/10.1002/jps.21659] [PMID: 19130605]
[11]
Xiao, L.; Yi, T. Liu, Zhou, H. The in vitro lipolysis of lipid-based drug delivery systems: A newly identified relationship between drug release and liquid crystalline phase. BioMed Res. Int., 2016, 20(16), 1-9.
[12]
Reymond, J.P.; Sucker, H.; Vonderscher, J. In vitro model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res., 1988, 5(10), 673-676.
[http://dx.doi.org/10.1023/A:1015987223407] [PMID: 3244622]
[13]
Wickham, M.; Garrood, M.; Leney, J.; Wilson, P.D.G.; Fillery-Travis, A. Modification of a phospholipid stabilized emulsion interface by bile salt: Effect on pancreatic lipase activity. J. Lipid Res., 1998, 39(3), 623-632.
[PMID: 9548594]
[14]
Patton, J.S.; Carey, M.C. Inhibition of human pancreatic lipase-colipase activity by mixed bile salt-phospholipid micelles. Am. J. Physiol., 1981, 241(4), G328-G336.
[PMID: 7315970]
[15]
Dahan, A.; Hoffman, A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm. Res., 2006, 23(9), 2165-2174.
[http://dx.doi.org/10.1007/s11095-006-9054-x] [PMID: 16902814]
[16]
Li, Y.; McClements, D.J. New mathematical model for interpreting pH-stat digestion profiles: Impact of lipid droplet characteristics on in vitro digestibility. J. Agric. Food Chem., 2010, 58(13), 8085-8092.
[http://dx.doi.org/10.1021/jf101325m] [PMID: 20557040]
[17]
Zangenberg, N.H.; Müllertz, A.; Kristensen, H.G.; Hovgaard, L. A dynamic in vitro lipolysis model. I. controlling the rate of lipolysis by continuous addition of calcium. Eur. J. Pharm. Sci., 2001, 14(2), 115-122.
[http://dx.doi.org/10.1016/S0928-0987(01)00169-5] [PMID: 11500257]
[18]
Cuiné, J.F.; McEvoy, C.L.; Charman, W.N.; Pouton, C.W.; Edwards, G.A.; Benameur, H.; Porter, C.J. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J. Pharm. Sci., 2008, 97(2), 995-1012.
[http://dx.doi.org/10.1002/jps.21246] [PMID: 18064698]
[19]
Ali, H.; Nazzal, M.; Zaghloul, A.A.; Nazzal, S. Comparison between lipolysis and compendial dissolution as alternative techniques for the in vitro characterization of α-tocopherol self-emulsified drug delivery systems (SEDDS). Int. J. Pharm., 2008, 352(1-2), 104-114.
[http://dx.doi.org/10.1016/j.ijpharm.2007.10.023] [PMID: 18065173]
[20]
Han, S.F.; Yao, T.T.; Zhang, X.X.; Gan, L.; Zhu, C.; Yu, H.Z.; Gan, Y. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. Int. J. Pharm., 2009, 379(1), 18-24.
[http://dx.doi.org/10.1016/j.ijpharm.2009.06.001] [PMID: 19508887]
[21]
Verma, R.; Mittal, V.; Kaushik, D. Quality based design approach for improving oral bioavailability of valsartan loaded SMEDDS and study of impact of lipolysis on the drug diffu-sion. Drug Deliv. Lett., 2018, 8(2), 130-139.
[http://dx.doi.org/10.2174/2210303108666180313141956]
[22]
Thomas, N.; Richter, K.; Pedersen, T.B.; Holm, R.; Müllertz, A.; Rades, T. In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate. AAPS J., 2014, 16(3), 539-549.
[http://dx.doi.org/10.1208/s12248-014-9589-4] [PMID: 24687210]
[23]
Sassene, P.J.; Knopp, M.M.; Hesselkilde, J.Z.; Koradia, V.; Larsen, A.; Rades, T.; Müllertz, A. Precipitation of a poorly soluble model drug during in vitro lipolysis: Characterization and dissolution of the precipitate. J. Pharm. Sci., 2010, 99(12), 4982-4991.
[http://dx.doi.org/10.1002/jps.22226] [PMID: 20574997]
[24]
Hu, M.; Li, Y.; Decker, E.A.; McClements, D.J. Role of calcium and calcium binding agents on the lipase digestibility of emulsified lipids using an in vitro digestion model. Food Hydrocoll., 2010, 24(8), 719-725.
[http://dx.doi.org/10.1016/j.foodhyd.2010.03.010]
[25]
Alvarez, F.J.; Stella, V.J. The role of calcium ions and bile salts on the pancreatic lipase-catalyzed hydrolysis of triglyceride emulsions stabilized with lecithin. Pharm. Res., 1989, 6(6), 449-457.
[http://dx.doi.org/10.1023/A:1015956104500] [PMID: 2762220]
[26]
Wickham, M.; Garrood, M.; Leney, J.; Wilson, P.D.G.; Fillery-Travis, A. Modification of a phospholipid stabilized emulsion interface by bile salt: Effect on pancreatic lipase activity. J. Lipid Res., 1998, 39(3), 623-632.
[PMID: 9548594]
[27]
Larsen, A.T.; Ohlsson, A.G.; Polentarutti, B.; Barker, R.A.; Phillips, A.R.; Abu-Rmaileh, R.; Dickinson, P.A.; Abrahamsson, B.; Ostergaard, J.; Müllertz, A. Oral bioavailability of cinnarizine in dogs: Relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur. J. Pharm. Sci., 2013, 48(1-2), 339-350.
[http://dx.doi.org/10.1016/j.ejps.2012.11.004] [PMID: 23178440]
[28]
Ye, A.; Cui, J.; Zhu, X.; Singh, H. Effect of calcium on the kinetics of free fatty acid release during in vitro lipid digestion in model emulsions. Food Chem., 2013, 139(1-4), 681-688.
[http://dx.doi.org/10.1016/j.foodchem.2013.02.014] [PMID: 23561161]
[29]
Di Maio, S.; Carrier, R.L. Gastrointestinal contents in fasted state and post-lipid ingestion: In vivo measurements and in vitro models for studying oral drug delivery. J. Control. Release, 2011, 151(2), 110-122.
[http://dx.doi.org/10.1016/j.jconrel.2010.11.034] [PMID: 21134406]
[30]
Chatterjee, B.; Hamed Almurisi, S.; Ahmed Mahdi Dukhan, A.; Mandal, U.K.; Sengupta, P. Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view. Drug Deliv., 2016, 23(9), 3639-3652.
[http://dx.doi.org/10.1080/10717544.2016.1214990] [PMID: 27685505]
[31]
Reymond, J.P.; Sucker, H.; Vonderscher, J. In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res., 1988, 5(10), 677-679.
[http://dx.doi.org/10.1023/A:1015939307478] [PMID: 3244623]
[32]
Khoo, S.M.; Humberstone, A.J.; Porter, C.J.H.; Edwards, G.A.; Charman, W.N. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halo-fantrine. Int. J. Pharm., 1998, 167, 155-164.
[http://dx.doi.org/10.1016/S0378-5173(98)00054-4]
[33]
Bates, T.R.; Carrigan, P.J. Apparent absorption kinetics of micronized griseofulvin after its oral administration on single- and multiple-dose regimens to rats as a corn oil-in-water emulsion and aqueous suspension. J. Pharm. Sci., 1975, 64(9), 1475-1481.
[http://dx.doi.org/10.1002/jps.2600640910] [PMID: 1185560]
[34]
Christophersen, P.C.; Christiansen, M.L.; Holm, R.; Kristensen, J.; Jacobsen, J.; Abrahamsson, B.; Müllertz, A. Fed and fasted state gastro-intestinal in vitro lipolysis: In vitro in vivo relations of a conventional tablet, a SNEDDS and a solidified SNEDDS. Eur. J. Pharm. Sci., 2014, 57, 232-239.
[http://dx.doi.org/10.1016/j.ejps.2013.09.007] [PMID: 24056027]
[35]
Dahan, A.; Hoffman, A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur. J. Pharm. Biopharm., 2007, 67(1), 96-105.
[http://dx.doi.org/10.1016/j.ejpb.2007.01.017] [PMID: 17329087]
[36]
Porter, C.J.; Kaukonen, A.M.; Boyd, B.J.; Edwards, G.A.; Charman, W.N. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res., 2004, 21(8), 1405-1412.
[http://dx.doi.org/10.1023/B:PHAM.0000036914.22132.cc] [PMID: 15359575]
[37]
Fatouros, D.G.; Nielsen, F.S.; Douroumis, D.; Hadjileontiadis, L.J.; Mullertz, A. In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. Eur. J. Pharm. Biopharm., 2008, 69(3), 887-898.
[http://dx.doi.org/10.1016/j.ejpb.2008.01.022] [PMID: 18367386]
[38]
Dahan, A.; Hoffman, A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci., 2005, 24(4), 381-388.
[http://dx.doi.org/10.1016/j.ejps.2004.12.006] [PMID: 15734305]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy